CA2638828C - Peptides immunomodulateurs et antitumeurs issus de la proteine limulus antilipopolysaccharide - Google Patents

Peptides immunomodulateurs et antitumeurs issus de la proteine limulus antilipopolysaccharide Download PDF

Info

Publication number
CA2638828C
CA2638828C CA2638828A CA2638828A CA2638828C CA 2638828 C CA2638828 C CA 2638828C CA 2638828 A CA2638828 A CA 2638828A CA 2638828 A CA2638828 A CA 2638828A CA 2638828 C CA2638828 C CA 2638828C
Authority
CA
Canada
Prior art keywords
peptide
peptides
lps
tumor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2638828A
Other languages
English (en)
Other versions
CA2638828A1 (fr
Inventor
Maribel Guerra Vallespi
Isis Del Carmen Torrens Madrazo
Osvaldo Reyes Acosta
Hilda Elisa Garay Perez
Gerardo Enrique Guillen Nieto
Boris Ernesto Acevedo Castro
Raimundo Ubieta Gomez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Publication of CA2638828A1 publication Critical patent/CA2638828A1/fr
Application granted granted Critical
Publication of CA2638828C publication Critical patent/CA2638828C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur le développement de peptides issus de la séquence HYRIKPTFRRLKWKKYKGKFW, et dans laquelle on a introduit des substitutions d'acides aminés, qui assurent la dissociation de la capacité de liaison au lipopolysaccharide, et qui potentialisent l'effet anti-tumoral et immunomodulateur. Lesdits peptides et leurs combinaisons peuvent être utilisés dans le traitement du cancer, ainsi qu'en synergie avec les thérapies classiques.
CA2638828A 2006-02-24 2007-02-23 Peptides immunomodulateurs et antitumeurs issus de la proteine limulus antilipopolysaccharide Expired - Fee Related CA2638828C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2006-0047 2006-02-24
CU20060047A CU23582A1 (es) 2006-02-24 2006-02-24 Péptidos con capacidad anti-tumoral e inmunomoduladora
PCT/CU2007/000006 WO2007095867A1 (fr) 2006-02-24 2007-02-23 Peptides avant une propriete anti-tumorale et immunomodulatrice

Publications (2)

Publication Number Publication Date
CA2638828A1 CA2638828A1 (fr) 2007-08-30
CA2638828C true CA2638828C (fr) 2014-09-09

Family

ID=38123823

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2638828A Expired - Fee Related CA2638828C (fr) 2006-02-24 2007-02-23 Peptides immunomodulateurs et antitumeurs issus de la proteine limulus antilipopolysaccharide

Country Status (16)

Country Link
US (1) US8283324B2 (fr)
EP (1) EP1992638B1 (fr)
JP (1) JP5069250B2 (fr)
KR (1) KR101456205B1 (fr)
CN (1) CN101426813B (fr)
AR (1) AR059608A1 (fr)
AT (1) ATE493434T1 (fr)
AU (1) AU2007218671B2 (fr)
BR (1) BRPI0708148B1 (fr)
CA (1) CA2638828C (fr)
CU (1) CU23582A1 (fr)
ES (1) ES2358845T3 (fr)
MX (1) MX2008010893A (fr)
RU (1) RU2430109C2 (fr)
WO (1) WO2007095867A1 (fr)
ZA (1) ZA200807034B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23674A1 (es) * 2007-07-31 2011-05-27 Ct Ingenieria Genetica Biotech Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica
EP2108372A1 (fr) * 2008-04-09 2009-10-14 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Nouveaux peptides antimicrobiens
WO2011029980A1 (fr) * 2009-09-11 2011-03-17 Proyecto De Biomedicina Cima, S.L. Compositions thérapeutiques pour le traitement de maladies provoquées par le pvh
CU23897B1 (es) 2010-05-31 2013-05-31 Ct De Ingeniería Genética Y Biotecnología Péptido para la terapia del cáncer
CN103724412A (zh) * 2013-09-29 2014-04-16 中国科学院海洋研究所 中国明对虾抗脂多糖因子及其制备和应用
WO2024006746A1 (fr) * 2022-06-29 2024-01-04 Cdres Pharma Llc Polypeptide actif sur le plan immunologique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0664814A1 (fr) * 1993-08-18 1995-08-02 MorphoSys AG Peptides liant et neturalisant les lipopolysaccharides
CU22700A1 (es) * 1997-09-29 2001-07-31 Ct Ingenieria Genetica Biotech Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso
WO2002038164A1 (fr) 2000-11-08 2002-05-16 Lorus Therapeutics Inc. Preparation combinee d'un modificateur de reponse biologique et d'un agent anticancereux et utilisations de cette derniere

Also Published As

Publication number Publication date
JP5069250B2 (ja) 2012-11-07
CN101426813A (zh) 2009-05-06
CU23582A1 (es) 2010-10-30
AR059608A1 (es) 2008-04-16
US20090221508A1 (en) 2009-09-03
WO2007095867A1 (fr) 2007-08-30
CA2638828A1 (fr) 2007-08-30
EP1992638B1 (fr) 2010-12-29
KR20080106446A (ko) 2008-12-05
US8283324B2 (en) 2012-10-09
ES2358845T3 (es) 2011-05-16
ZA200807034B (en) 2009-06-24
BRPI0708148B1 (pt) 2019-01-15
CN101426813B (zh) 2012-04-04
RU2008137968A (ru) 2010-03-27
RU2430109C2 (ru) 2011-09-27
EP1992638A1 (fr) 2008-11-19
MX2008010893A (es) 2008-09-03
BRPI0708148A2 (pt) 2011-05-17
KR101456205B1 (ko) 2014-10-31
ATE493434T1 (de) 2011-01-15
AU2007218671B2 (en) 2012-02-09
AU2007218671A1 (en) 2007-08-30
JP2009527510A (ja) 2009-07-30

Similar Documents

Publication Publication Date Title
CA2638828C (fr) Peptides immunomodulateurs et antitumeurs issus de la proteine limulus antilipopolysaccharide
JP2023106599A (ja) タンパク質抗原およびその使用
JP5294271B2 (ja) Ｃｄｈ３ペプチド及びこれを含む薬剤
US7846651B2 (en) Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same
TWI714558B (zh) 來自gpc3之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法
JP5789820B2 (ja) 血管内皮増殖因子受容体１に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン
US20130225502A1 (en) Combination therapy with w t 1 peptide vaccine and temozolomide
EP3773673A2 (fr) Composés immunogènes pour le traitement de la fibrose, de maladies auto-immunes et d'une inflammation
JP4780540B2 (ja) サバイビン由来癌抗原ペプチド
RU2758112C2 (ru) Индуктор иммунитета
WO2023163094A1 (fr) Composition pharmaceutique pour le traitement ou la prévention de la leucémie à lymphocytes t de l'adulte
WO2017170365A1 (fr) Agent induisant l'immunité

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20200224